Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23514417 | 0.83 | CA12 (0.49) | RAD52NPC1CA12CA1CA2 | |
| SCHEMBL23514413 | 0.83 | CA12 (0.49) | RAD52NPC1CA12CA1CA2 | |
| SCHEMBL23514416 | 0.81 | RAB9A (0.49) | RAD52NPC1CA12CA1CA2 | |
| SCHEMBL23514433 | 0.81 | RAB9A (0.49) | RAD52NPC1CA12CA1CA2 | |
| SCHEMBL17152580 | 0.80 | NPC1 (0.47) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL266522 | 0.80 | CYP1A2 (0.55) | DPP7TSHRALDH1A1CYP1A2MAPK1 | |
| SCHEMBL7166332 | 0.80 | CYP1A2 (0.55) | DPP7TSHRALDH1A1CYP1A2MAPK1 | |
| SCHEMBL23099381 | 0.80 | CYP1A2 (0.55) | DPP7TSHRALDH1A1CYP1A2MAPK1 | |
| SCHEMBL4166662 | 0.79 | KIF11 (0.42) | RAD52NPC1CA12CA1CA2 | |
| SCHEMBL30392344 | 0.79 | CA12 (0.51) | RAD52NPC1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1864994-B1 | PAR-2 AGONIST | KOWA CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1864994-A1 | PAR-2 AGONIST | Kowa Company, Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215703-A1 | PAR-2 Agonist | FPR2, F2RL1, FPR3 | RAD52 3246/4885NPC1 1910/4885CA12 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.